Characteristics of Circular RNA Expression in Ishikawa Human Endometrial Carcinoma Cells with Progesterone Treatment

Lihua Wang  
the International Peace Maternity & Child Health Hospital of China Welfare Institute (IPMCH), Shanghai Jiaotong University

Panchan Zheng  
The International Peace Maternity & Child Health Hospital

Wenjiao Cao  
The International Peace Maternity & Child Health Hospital

Xiao Sun  
The International Peace Maternity & Child Health Hospital

Wuyuan Gao  
The International Peace Maternity & Child Health Hospital

Yudong Wang (owangyudong@126.com)  
The International Peace Maternity & Child Health Hospital

Research article

**Keywords:** endometrial cancer, progesterone, circRNA, miRNA, medroxyprogesterone acetate

**DOI:** https://doi.org/10.21203/rs.3.rs-30247/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Progestins are commonly used as the conservative endocrine treatment of young early endometrial cancer (EC) patients. Circular RNAs (circRNAs) are new group players in multiple cellular functions. This study aims to identify the differentially expressed circular RNAs (DE-circRNAs) in endometrial cancer (EC) cells upon the progesterone treatment, aiding in the understanding of the impact of circRNAs in progestin therapy.

Methods

RNA-seq analysis was used to identify the DE-circRNAs between MPA-treated and -non-treated Ishikawa cell lines. Functional enrichment analysis and circRNA-miRNA interaction network analysis were applied to these DE-circRNAs, validated by qRT-PCR analyses. Moreover, shRNA knockdown was utilized to explore the circRNA function.

Results

A total of 87 circRNAs were differentially expressed in Ishikawa cell lines with MPA treatment compared with that of control cells (|fold change| ≥ 2.0, p < 0.05). Besides, these circRNAs were mainly enriched in cancer-related pathways, including response to cholesterol, epithelial to mesenchymal transition, and base-excision repair. The competing endogenous RNA (ceRNA) network showed that miR-296-3p, miR-1236-3p, and miR-144-5p were related to cancer. Furthermore, the qPCR results were coincident with the RNA-seq data. Of note, hsa_circ_0001860 was significantly induced upon MPA treatment. Knockdown of hsa_circ_0001860 can partially rescue the MPA-inhibited cell proliferation and invasion and regulate the expression of its interacting miRNAs.

Conclusions

This is the first time to evaluate the circRNA expression profile in progesterone treatment for EC. These circRNAs (e.g., hsa_circ_0001860) may be used as potential diagnostic biomarkers and treatment targets for the evaluation of EC progesterone treatment.

Background

Endometrial cancer (EC) is the most common gynecologic malignancy of the female genital tract (1). Currently, the standard treatment of EC includes total abdominal hysterectomy and bilateral salpingo-oophorectomy (BSO) (2). However, hysterectomy is not an acceptable therapy for young patients without children. With an increasing number of women electing to delay childbearing, there is a critical need for
adequate treatment without hysterectomy for nulliparous women with EC (3). Progestins, are widely used in young early EC patients as conservative endocrine treatment (4). Progesterone, a tumor suppressor in the endometrium, plays a critical role in cell differentiation, cycle, and apoptosis (5). Approximately 90% of young patients can be treated with progestin due to a high expression of progesterone receptor (PR), which often results in a good prognosis (4). A meta-analysis indicates that 72 percent of patients achieved remission by oral progesterone, and the pregnancy outcome is about 35–40% (6, 7). However, a follow-up study shows that 35.4% of patients treated with progesterone have a recurrence after an initial response (p = 0.03), and 25.4% of them suffer persistent disease (p = 0.02) (8). In addition, according to clinical data, 30 percent of young patients fail to respond to progestin due to the possessed drug resistance during progestin treatment (4), and in turn, receptor-negative patients have been reported to respond to hormone treatment (7, 9). Accordingly, drug resistance is a major challenge during the treatment of endometrial cancer. However, the molecular mechanisms underlying progestin therapy and progestin resistance still confused.

The recent advances in circular RNA (circRNA), a single-stranded, covalently closed circular molecule acting as microRNA (miRNA) sponges to sequester miRNA of a particular family, opened up a new direction for exploring the pathogenesis of EC. CircRNA is a competitive inhibitor that suppresses one miRNA binding to its mRNA targets and regulates gene expression via functioning as ceRNA in distinct physiological and pathological states (10, 11). CircRNA is more suitable than other RNA types to be a biomarker due to its stable structure, as well as high cell-type-, tissue- and developmental-specific expression (10, 12). In cervical cancer, Wang et al. identified 44 novel circRNAs, which may be associated with cancer (11). In EC, Xu et al. identified 209 up-regulated circRNAs and 66 down-regulated circRNAs in extracellular vesicles (EVs) of patients with stage III adenocarcinoma endometrial cancer (13). However, no research has investigated the effect of MPA on the expression profiles of circRNAs and the function of MPA-regulated circRNAs.

Herein, this study performed RNA-seq analysis of Ishikawa human endometrial carcinoma cells (ISK) treated with MPA or not. First, 46 up-regulated circRNAs and 41 down-regulated circRNAs were identified in ISK cells treated with MPA compared with the untreated cells. Second, gene functional enrichment analysis was performed, and we identified the top 10 significant GO terms and KEGG pathways. Third, the circRNA-miRNA networks were constructed to investigate the interaction of circRNAs and miRNAs. In addition, we verified the expression levels of selected circRNAs by qRT-PCR and investigated the function of the MPA-induced circRNA.

**Methods**

**Cell culture**

ISK are maintained by our laboratory. They were established by Nishida et al (14) from an endometrial adenocarcinoma with characteristics of ER-positive and PR-positive in 1985. ISK cells (ATCC) were cultured in Dulbecco’s Modified Eagle’s Medium (HyClone) supplemented with 10% fetal bovine serum
(HyClone) at 37 °C under an atmosphere of 5% CO2. A group of ISK cell lines were treated with MPA (selleck, USA). Untreated ISK cell lines were used as controls. Previous study indicated that there was a positive correlation between the dose-dependent of MPA and reducing the growth of parental Ishikawa cells (15). Hence, Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum, and MPA (selleck, USA) was added 10 µM. The treatment stocks were initially prepared in DMSO (vehicle) with subsequent dilution for experiments of more than 1:1000 (for 10 − 5 M). The presence of a vehicle at such dilutions has previously been demonstrated to have no effect on cell growth.

Rna Extraction And Quality Control

Three samples from each of the ISK/MPA and ISK cell lines were collected, and tRNA isolation Total RNA was isolated by using Trizol reagent (Invitrogen life, USA) following the manufacturer’s instructions. The quantity and quality of the RNA samples were determined using the NanoDrop ND-1000 instrument (Thermo Fisher Scientific, Waltham, MA, USA). And then RNA Integrity and gDNA contamination test were conducted by Denaturing Agarose Gel Electrophoresis. Sequencing library was determined by Agilent 2100 Bioanalyzer using the Agilent DNA 1000 chip kit (Agilent, part # 5067 – 1504). The isolated RNA was stored at -80 °C for further experimental verification.

Circrna Rna-seq

CircRNA-Seq high throughput sequencing and subsequent bioinformatics analysis were all performed by Cloud-Seq Biotech (Shanghai, China). The circRNA sequencing library was constructed by the total RNA from each sample. First of all, pretreating 5 µg total RNA by CircRNA Enrichment Kit (Cloud-seq Inc, USA); Secondly, the prepared RNAs was used to construct the RNA libraries; Then, libraries were controlled for quality and quantified using the BioAnalyzer 2100 system. In addition, libraries were denatured as single-stranded DNA molecules, captured on Illumina flow cells, amplified in situ as clusters and finally sequenced for 150 cycles on Illumina HiSeq Sequencer according to the instructions.

Circrna Rna-seq Data Analysis

Paired-end reads were harvested from Illumina HiSeq 4000 sequencer, and quality controlled by Q30. After 3’ adaptor-trimming and low quality read removing by cutadapt software (v1.9.3), the reads were aligned to the reference genome/transcriptome by STAR software, and circRNA were detected and annotated by DCC software. CircBase database and circ2Trait disease database were used to annotate the identified circRNA. The junction read counts were normalized, and differentially expressed circRNA were determined using the edgeR package of R software. P < 0.05 was set as a threshold. GO, and Pathway enrichment analysis was performed by using the host genes of the differentially expressed circRNA. CircRNA-miRNA interaction analysis was performed, and the network was constructed by Cytoscape software. Cytoscape (https://cytoscape.org/) is an open-source software platform for
visualizing complex networks and integrating these with any attribute data. We generated a Cluster plot to identify the hosting genes of circRNAs by utilizing R3.2.2, which is from the R package – “hclust(method = "single")

Experimental Validation With Quantitative Rt-pcr

We screened 20 circRNAs for experimental validation using quantitative RT-PCR. Total RNA was extracted and reversely transcribed into cDNA using SuperScriptTM III Reverse Transcriptase (Invitrogen). The expression levels of circRNAs was determined by ViiA 7 Real-time PCR System (Applied Biosystems). Triplicates were performed for each sample in three independent experiments. The primers were designed using the “Out-facing” strategy to guarantee the amplifications were from circle template. Relative expression ratio ($\Delta\Delta CT$) of each circRNA is presented in a log 2 value. miScript PCR Starter Kit (Qigen) was utilized to set-up of miRNA quantification experiment. The sequences of primers for circRNAs and miRNAs was included in Table 3.

Cell Proliferation Assay, Invasion Assay, And ShRNA Knockdown Experiment

We utilized CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) kit (# G3582) from Promega to examine cell proliferation (16). Standard 24-well Boyden control and invasion chambers (BD Biosciences) were used to assess cell migration and invasion following manufacturer suggestions. We cloned shRNAs into pGPU6/GFP/Neo vectors. The sequence of shRNA targeting hsa_circ_0001860-2 is “TTACTGAAGCTTCAAGGTTAC”; and the control shRNA sequence is “TTCTCCGAACGTGTCACGT”.

Data analysis

Statistical analysis Data is presented as the mean standard error (SE) for triplicate measurements. Student’s t test was using to estimate the significance of data (Statistically significant : $P < 0.05$).

Results

Identification of dysregulated circRNAs in ISK cells upon the MPA treatment

The concentration and purity of total RNAs from different samples were determined by NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA). All RNA samples showed an OD A260/280 ratio between 1.8 and 2.1. Principal Component Analysis (PCA) of these sequenced samples showed that there was a clear separation relationship between the treated cells and control cells (Supplemental Data 1). RNA-seq analysis showed that a total of 4,814 circRNAs were detected. Among them, 964 circRNAs were novel according to the published studies. We then compared the expression profiles of circRNAs between
MPA-treated-ISK cells and control cells. The results showed 87 differentially expressed circRNAs in MPA-treated-ISK cells compared with control cells (|fold change| ≥2.0, p < 0.05), among them 46 up-regulated and 41 down-regulated (Fig. 1). It is reported that circRNA is divided into exotic circular RNA (ecircRNA), circular intronic RNA (ciRNAs), and exonic-intron circular RNA (EiciRNA) (17). In this study, all circRANs are located in exons. Moreover, we conducted a clustering analysis of these circRNAs and their hosting genes (Supplemental Data 2 and 3).

Go And Kegg Pathway Analyses

Gene Ontology (GO) includes biological process classification (BP), cellular component classification (CC), and molecular function classification (MF). Top 10 dysregulated GO analysis of each domain were identified according to enriched up-regulated or down-regulated circRNAs (Figs. 2A-B). GO terms with P-value < 0.05 were selected and ranked by enrichment score (-log10 (P-value)). Among the BP terms, response to cholesterol, epithelial to mesenchymal transition, and base-excision repair have been reported to be associated with tumor (6, 18–21). In MF terms, WNT-activated receptor activity and WNT-protein binding might play a role in tumors.

KEGG analysis showed that the down-regulated circRNAs were mainly enriched in renal cell carcinoma, thyroid hormone signaling pathway, and pathways in cancer (Fig. 2C). While the up-regulated circRNAs were mainly enriched in protein processing in the endoparasitic reticulum, chronic myeloid leukemia, and RNA degradation (Fig. 2D).

Competing Endogenous Rna (cerna) Network Analysis

It was reported that mRNAs and circRNAs act as ceRNAs, or miRNA sponges to communicate with each other by competing for miRNA-binding through common miRNA response elements (22). In addition, circRNAs have been reported to sequester relevant miRNAs via miRNA response elements to regulate gene expression post-transcriptionally (22). To investigate circRNA regulation in MPA-treated EC cells, we investigated miRNA-circRNA interactions. We identified miRNAs that paired with the differentially expressed circRNAs. And in total, we obtained 25 miRNA-circRNA interaction pairs. And then, we constructed the circRNA-miRNA network (Fig. 3). The parameter of the network was listed in Supplemental Data 4. The top 5 differentially expressed circRNAs that interacts with multiple miRNA partners were hsa_circ_0020028, hsa_circ_0001860, hsa_circ_0001993, hsa_circ_0105045, and hsa_circ_0046843. The five circRNAs were treated with RNase R, and qPCR analyses were used to compare the gene expression level changes pre- and post-treatment. In contrast to the > 10000-fold change of control GAPDH, all the five circRNAs had less than a 3-fold change, proving that they are circle RNA (Table 1). In addition, Sanger sequencing was performed to determine the cyclization site of those circRNAs (Supplemental Data 5). The network analysis showed that different circRNA bound to the same miRNAs, suggesting that regulation of miRNAs by circRNA was complicated. These five circRNAs were all
paired with hsa-miR-4753-3p (Fig. 3). Some of the miRNAs have been reported to be associated with cancer treatment or progression, including miR-296-3p (23), miR-1236-3p (24), and miR-144-5p (25).

### Table 1
qPCR analysis of gene expression level changes before and after treatment.

| Gene | Rnase R | Mock | Ct(RnaseR) - Ct(Mock) | Fold Enrichment | Mock | Rnase R |
|------|---------|------|-----------------------|----------------|------|---------|
| GAPDH | 30.777 | 17.474 | 13.303 | 10107.434 | 1.000 | 0.000 |
| chr10:112723883–112745523+ (hsa_circ_0020028) | 24.332 | 23.637 | 0.695 | 1.619 | 1.000 | 0.618 |
| chr9:37126309–37126939+ (hsa_circ_0001860) | 24.553 | 23.682 | 0.871 | 1.829 | 1.000 | 0.547 |
| chr18:74561482–74583781+ (hsa_circ_0001993) | 22.440 | 21.255 | 1.185 | 2.274 | 1.000 | 0.440 |
| chr16:14674731–14721193- (hsa_circ_0105045) | 28.187 | 27.753 | 0.434 | 1.351 | 1.000 | 0.740 |
| chr18:9195549–9221997+ (hsa_circ_0046843) | 20.533 | 19.859 | 0.674 | 1.596 | 1.000 | 0.627 |
Validation Of The Expression Levels Of CircRNAs Using QRT-PCR

In order to confirm the RNA-seq data, we screened 20 differentially expressed circRNAs to validate their expression levels by qRT-PCR, including ten up-regulated circRNAs and ten down-regulated circRNAs (Table 2). In addition, the expression levels of the five circRNAs in the network were also detected. The qRT-PCR analysis revealed that the expression of these circRNAs showed either the same up-regulation pattern or the same down-regulation pattern as the RNA-seq data. Particularly, hsa_circ_0020028 (circRNA-1) and hsa_circ_0001860 (circRNA-7) were up-regulated in ISK cell line treated with progesterone compared with untreated cells, while hsa_circ_0001993 (circRNA-8), hsa_circ_0105045 (circRNA-12) and hsa_circ_0046843 (circRNA-13) were down-regulated, which is consistent with our RNA-seq results (Fig. 4). These findings indicated that the results of qRT-PCR were well consistent with RNA-seq results, suggesting the high reliability of the RNA-seq expression results.
Table 2
Twenty differentially expressed circRNAs were validated by qRT-PCR

| num | Cir | log FC PV | cir | Gene Name |
|-----|-----|----------|-----|-----------|
| NA | -ID | 2.8 71 29 | hs a_cir | SH OC 2 |
| NA-1 | chr 10:11 | 27 88 3-11 27 45 52 3+ | HS a_cir | 00 02 8 |
| NA-2 | chr 14:62 18 71 00-62 18 85 41 + | hs a_cir | 00 06 39 3 |
| NA-3 | chr 13:20 53 40 98-20 56 80 59 + | hs a_cir | Z M Y M 2 |
| NA-4 | chr 20:39 72 11 12-39 72 99 93 + | hs a_cir | TO P1 |

| cir | chr -4 | 0.0 | hs DN |
| chr | cR  | NA |  a_ | cir | A2 |
|-----|-----|----|-----|-----|----|
| 10: | 15  | 20 |     |     |    |
| 70  | 7   |    |     |     |    |
| 19  |     |    |     |     |    |
| 67  | 00  |    |     |     |    |
| 68- | 18  |    |     |     |    |
| 70  | 52  |    |     |     |    |
| 22  | 4   |    |     |     |    |
| 99  |     |    |     |     |    |
| 20- |     |    |     |     |    |

| chr | cR  | NA |  a_ | cir | A2 |
|-----|-----|----|-----|-----|----|
| 3:5 |     |    |     |     |    |
| 66  |     |    |     |     |    |
| 26  |     |    |     |     |    |
| 99  |     |    |     |     |    |
| 8-  |     |    |     |     |    |
| 56  |     |    |     |     |    |
| 62  |     |    |     |     |    |
| 80  |     |    |     |     |    |
| 56  |     |    |     |     |    |

| chr | cR  | NA |  a_ | cir | A2 |
|-----|-----|----|-----|-----|----|
| 9:3 |     |    |     |     |    |
| 71  |     |    |     |     |    |
| 26  |     |    |     |     |    |
| 30  |     |    |     |     |    |
| 9-  |     |    |     |     |    |
| 37  |     |    |     |     |    |
| 12  |     |    |     |     |    |
| 69  |     |    |     |     |    |
| 39  |     |    |     |     |    |

| chr | cR  | NA |  a_ | cir | A2 |
|-----|-----|----|-----|-----|----|
| 18: |     |    |     |     |    |
| 74  |     |    |     |     |    |
| 56  |     |    |     |     |    |
| 14  |     |    |     |     |    |
| 82- |     |    |     |     |    |
| 74  |     |    |     |     |    |
| 58  |     |    |     |     |    |
| 37  |     |    |     |     |    |
| 81  |     |    |     |     |    |

| chr | cR  | NA | /   | M   | 1A |
|-----|-----|----|-----|-----|----|
| 2:7 |     |    | 80  | 3   |    |
| 48  |     |    |     | 34  |    |
| 34  |     |    |     | 18  |    |
| 18  |     |    |     | 2-  |    |
| 74  |     |    |     | 86  |    |
| 74  |     |    |     | 54- |    |

| chr | cR  | NA |  a_ | cir | A2 |
|-----|-----|----|-----|-----|----|
| 7:1 |     |    | 04  | 30  |    |
| 57  |     |    |     |     |    |
| chr | chr | 0.0 | 0.0 | cir | cR | NA | 10 | 61- | 15 | 70 | 24 | 02 | 1+ |
|-----|-----|------|------|-----|----|----|----|-----|----|----|----|----|----|
| -   | 00  | c_   | 01   | 33  | 80 | 5  | 24 | 02  | 11 | 68 | 42-|    |    |
| cR  | 4:8 | -4   | 0.0  | a_  | cir| 15 | 11 | 35  | 88 | 11 | 68 | 42-|    |
| NA  | 81  | 27   | 15   | c_  | cir| 9  | 04 | 00  | 06 | 86 | 6  |    |    |
| -   | 11  | 35   | 15   | c_  | cir| 9  | 04 | 86  | 06 | 6  |    |    |    |

| chr | chr | 0.0 | 0.0 | cir | cR | NA | 12 | 67- | 14 | 47 | 31-| 14 | 72 | 11 | 93-|
|-----|-----|------|------|-----|----|----|----|-----|----|----|----|----|----|----|
| -   | 00  | c_   | 01   | 05  | 04 | 5  | 67 | 01  | 04 | 5  |    |    |    |
| cR  | 16: | -3   | 0.0  | a_  | cir| 1  | 14 | 01  | 04 | 5  |    |    |    |
| NA  | 14  | 85   | 38   | c_  | cir| 1  | 14 | 04  | 5  |    |    |    |    |
| -   | 12  | 67   | 01   | 05  | 04 | 5  |    |    |    |    |    |    |

| chr | chr | 0.0 | 0.0 | cir | cR | NA | 13 | 95- | 92 | 21 | 99 | 7+ |    |    |
|-----|-----|------|------|-----|----|----|----|-----|----|----|----|----|----|
| -   | 00  | c_   | 00   | 00  | 00 | 6  | 95 | 92  | 99 | 7+ |    |    |    |
| cR  | 18: | -3   | 0.0  | a_  | cir| 7  | 91 | 46  | 84 | 3  |    |    |    |
| NA  | 91  | 91   | 34   | c_  | cir| 7  | 91 | 46  | 84 | 3  |    |    |
| -   | 13  | 95   | 00   | 46  | 84 | 3  |    |    |    |    |    |    |

| chr | chr | 0.0 | 0.0 | cir | cR | NA | 14 | 09- | 07 | 90 | 93 | 92 | 8- |    |
|-----|-----|------|------|-----|----|----|----|-----|----|----|----|----|----|
| -   | 00  | c_   | 00   | 00  | 11 | 6  | 09 | 07  | 90 | 93 | 92 | 8- |    |
| cR  | 2:2 | 3.0  | 17   | a_  | cir| 71 | 09 | 07  | 90 | 93 | 92 | 8- |    |
| NA  | 39  | 71   | 17   | c_  | cir| 09 | 09 | 07  | 90 | 93 | 92 | 8- |    |
| -   | 14  | 09   | 00   | 00  | 11 | 6  |    |    |    |    |    |    |    |

| chr | chr | 0.0 | 0.0 | cir | cR | NA | 15 | 60- | 97 | 11 | 08 |    |    |
|-----|-----|------|------|-----|----|----|----|-----|----|----|----|----|
| -   | 00  | c_   | 00   | 00  | 08 |    |    |    |    |    |    |    |
| cR  | 10: | -3   | 0.0  | a_  | cir| 95 | 60 | 97  | 11 |    |    |    |
| NA  | 12  | 5    | 33   | c_  | cir| 95 | 60 | 97  | 11 |    |    |
| -   | 15  | 95   | 33   | 00  | 08 |    |    |    |    |    |    |    |    |

Page 11/30
| chr | chr | 4.3 | 0.0 | hs | SE |
|-----|-----|-----|-----|----|----|
| NA  | 6:1 | 90  | 12  | a_ | C6 |
| NA  | -   | 22  |     | cir| 3  |
| 16  | 58  | 00  |     |    |    |
| 33- | 10  | 14  |     |    |    |
| 10  | 82  | 4   |     |    |    |
| 46  | 13  |     |    |    |    |
| 6-  |     |     |    |    |    |

| chr | chr | 3.1 | 0.0 | hs | NE |
|-----|-----|-----|-----|----|----|
| NA  | 4:1 | 70  | 10  | a_ | IL3|
| NA  | -   | 27  |     | cir|    |
| 17  | 44  | 00  |     | c_ |    |
| 62- | 17  | 01  |     |    |    |
| 82  | 74  | 45  |     |    |    |
| 88  | 2+  | 9   |     |    |    |

| chr | chr | 3.8 | 0.0 | /  | PY |
|-----|-----|-----|-----|----|----|
| NA  | 15: | 24  | 49  |    | GO |
| NA  | -   | 83  |     |    |    |
| 18  | 57  | 82- |     |    |    |
| 55  | 83  | 74  |     |    |    |
| 23- |     |     |    |    |    |

| chr | chr | 4.4 | 0.0 | hs | LR |
|-----|-----|-----|-----|----|----|
| NA  | 4:1 | 72  | 09  | a_ | BA |
| NA  | -   | 71  |     | cir|    |
| 19  | 92  |     |     | c_ |    |
| 33- | 15  | 00  |     |    |    |
| 17  | 38  | 08  |     |    |    |
| 40  | 9-  | 61  |     |    |    |

| chr | chr | -2. | 0.0 | hs | S  |
|-----|-----|-----|-----|----|----|
| NA  | 18: | 02  | 25  | a_ | M  |
| NA  | -   | 45  |     | cir| AD |
| 20  | 39  | 00  |     | c_ |    |
| 20  | 14  | 00  |     |    |    |
| 30- |     |     |    |    |    |
Investigation Of The Representative Mpa-regulated Circrna (hsa_circ_0001860)

To examine the role of these identified MPA-regulated circRNAs, we have hsa_circ_0001860 as a representative one for the functional analysis. First, we validated the induction of hsa_circ_0001860 by the MPA treatment of ISK cells (Fig. 5A). As expected, MPA treatment of ISK cells inhibits the ISK cell proliferation, and this inhibition can be attenuated by the shRNA knockdown of hsa_circ_0001860 (Fig. 5B). It suggested that MPA inhibited cell proliferation partially through hsa_circ_0001860. Similar effects were observed in the cell invasion experiments upon the MPA treatment and the hsa_circ_0001860 knockdown (Fig. 5C). Moreover, the knockdown of hsa_circ_0001860 can regulate its interacting miRNAs, which were shown in the network analysis (Fig. 5D). Taken together, hsa_circ_0001860, which can be induced by MPA, inhibits cell proliferation and invasion, probably by regulating its interacting miRNAs.
| number   | CircRNA-ID            | circBase-ID       | Primers (5’-3’) |
|----------|-----------------------|-------------------|-----------------|
| circRNA-1 | chr10:112723883-112745523+ | hsa_circ_0020028 | Forward: CCAACCTTGACTTGCA GC  
|          |                       |                   | Reverse: TGCCCATTCTGATCA TTCA |
| circRNA-2 | chr14:62187100-62188541+ | hsa_circ_0006393 | Forward: TCCATGTGACCATGAG GAAA  
|          |                       |                   | Reverse: GAGATCTGGCTGCAT CTCG |
| circRNA-3 | chr13:20534098-20568059+ | /                 | Forward: TGAATGTGGCAGGAG ACG  
|          |                       |                   | Reverse: AGGGCTGAAGGCGAT TCT |
| circRNA-4 | chr20:39721112-39729993+ | hsa_circ_0115215 | Forward: GTGGAAAGAAGTCCG GCA  
|          |                       |                   | Reverse: TGGTGGGGCAAAATAC TGG |
| circRNA-5 | chr10:70196768-70229920- | hsa_circ_0018524 | Forward: CATGGTGCCATACCTG TCA  
|          |                       |                   | Reverse: CCAGGCGCTTTTCAC AGT |
| circRNA-6 | chr3:56626998-56628056+ | hsa_circ_0001313 | Forward: TGCTCTTTTGACCG AGC  
|          |                       |                   | Reverse: GAAAGGGTGCTCCAG CAGT |
| circRNA-7 | chr9:37126309-37126939+ | hsa_circ_0001860 | Forward: GCTGGATGCTACTGG GATG  
|          |                       |                   | Reverse: TGGGCATAATGAATTT |
| circRNA | chr     | start-end   | name         | Forward | Reverse |
|---------|---------|-------------|--------------|---------|---------|
| circRNA-8 | chr18:74561482-74583781+ | hsa_circ_0001993 | CACGTATTCGTGTCCG | TGGCGTTGAAACTGGGAT |
| circRNA-9 | chr2:74834182-74867454- | / | CGTGGACTCAGCGTC | CCACTCAACTGCCAGGA |
| circRNA-10 | chr7:157009561-157024021+ | hsa_circ_0133805 | CCCAACCAGGGGTTC | CAGCCAGTGGTTTGGAGG |
| circRNA-11 | chr4:88104355-88116842- | hsa_circ_0006866 | TCCATTCGGACTACCC | CCCACTCAACTGCCATG |
| circRNA-12 | chr16:14674731-14721193- | hsa_circ_0105045 | TCCATTCGGACTACCC | CCCACTCAACTGCCATG |
| circRNA-13 | chr18:9195549-9221997+ | hsa_circ_0046843 | GGAGCGTCCAGTGGA | TCCTTGCTCACATCAC |
| circRNA-14 | chr2:239090706-239093928- | hsa_circ_0001116 | CTCGGAGATAGTGGCAGGA | TCGAATTCCTCCATG |
| circRNA-15 | chr10:126097111-126100769- | hsa_circ_0008898 | GGCTGGAGAGACTGC | CTCGGAGATAGTGGCAGGA |
| circRNA   | Chr (Forward)                    | hsa_circ_ | Forward          | Reverse                  |
|-----------|----------------------------------|----------|------------------|--------------------------|
| circRNA-16| chr6:108225833-108246136-         | 0009144  | AATAGTAATGGCCCGG | GGAGGGCCTTGGACT          |
|           |                                  |          | AACC             |                          |
|           |                                  |          | GAACAATGCCCATCCT |                          |
|           |                                  |          | GC               |                          |
| circRNA-17| chr4:178274462-178274882+         | 0001459  | AAAAGCTGCAACCCCT | GAACAATGCCCATCCT         |
|           |                                  |          | GGA              |                          |
|           |                                  |          | CCAAATGCAGTTTTTC |                          |
|           |                                  |          | TGTCC            |                          |
| circRNA-18| chr15:55835782-55837423-          | /        | TTAAGTTTCAGTAGTT |                          |
|           |                                  |          | AGCTGT           |                          |
|           |                                  |          | TTCCTCATCTGCAATA |                          |
|           |                                  |          | TGTCC            |                          |
| circRNA-19| chr4:151719233-151738409-         | 0008618  | AGCCATGGACAAGAA  |                          |
|           |                                  |          | CTGCT            |                          |
|           |                                  |          | AAGGTGGAAGGTGAG  |                          |
|           |                                  |          | ACTGC            |                          |
| circRNA-20| chr18:45391430-45423180-          | 0000847  | TATTCAGAAACGCA   |                          |
|           |                                  |          | CCTG             |                          |
|           |                                  |          | TTCATCCCAGCAGTC  |                          |
|           |                                  |          | TCTT             |                          |

Note: / means a novel circRNA which has not been in circBase. Actin is the internal control. The forward primer of actin is (5'-3') GTGGCGAGGACTTTGATT. The reverse primer of actin is (5'-3') CTGTAACACGACTTCATT.

U6 (5'-3': GCTTCGGCAGCAGCATCATAAAAT ) is the internal control of qPCR analysis of miRNAs.
### Discussion

CircRNAs are initially reported by Hsu and Coca-Prados (26). Nevertheless, these CircRNAs were thought to be transcription errors. Now, researchers have discovered thousands of circRNAs which may serve as diagnostic or predictive biomarkers, such as hsa_circ_0005075 in hepatocellular carcinoma (27), as well as hsa_circ_002059, hsa_circ_0000190, and circPVT1 in gastric carcinoma (28–31), and all of this were benefited from bioinformatics analysis.

CircRNAs can regulate many cellular processes, including sponging miRNAs (32, 33), the assembly and transport of cellular proteins (34), alternative splicing and gene expression (35), possessing protein-coding activity, modulating generation of rRNAs/trRNAs (35), and antiviral immunity (36). Specifically, ciRS-7 is the first identified CircRNA sponging miR-7 with direct binding (32, 33). Foxo3 circular RNA (circ-Foxo3) binds to ID-1 (inhibitor of differentiation-1), the transcription factor E2F1, HIF-1α (hypoxia-inducible factor-1α) and FAK (focal adhesion kinase), and inhibits their translocation (34). The knockdown of circRNA EIF3J or circRNA PAIP2 significantly reduces the expression level of their parental genes (37). circRasGEF1B, which is conserved between human and mouse circRNA, positively regulates lipopolysaccharide (LPS) response (36).

However, no study has focused on circRNA regulation in EC with progesterone treatment. Therefore, in this study, we applied RNA-seq to investigate the differentially expressed circRNA in EC with progesterone treatment, and the results revealed that a total of 87 circRNAs were differentially expressed in MPA-treated-ISK cells compared control cells (|fold change| ≥ 2.0, p < 0.05). Furthermore, the expression levels of the top 20 significant expressed circRNAs were validated by qRT-PCR. Particularly, hsa_circ_0046843 was significantly down-regulated in the ISK cell line treated with progesterone, while hsa_circ_0001860 was significantly up-regulated. In addition, we performed GO and KEGG pathways analysis. Most of the BP terms in our study have been reported to be closely associated with cancer, including response to cholesterol, epithelial to mesenchymal transition, and base-excision repair. Firstly, cholesterol has been reported to play a role in the synthesis of estrogen and progesterone. 3β-Hydroxysteroid-Δ24 reductase (DHCR24), the final enzyme in the cholesterol biosynthetic pathway, has been demonstrated to aggravate cancer invasion and progesterone resistance in EC (18). Additionally, dietary cholesterol consumption, including saturated fatty acid, unsaturated fatty acid, and cholesterol intake, influences EC risk by regulating the production, metabolism, and excretion of endogenous hormones (6). Secondly, Epithelial-
to-Mesenchymal Transition (EMT) is an important step towards the invasion and metastasis of cancer (19). Hsu et al. demonstrated that epithelial cell adhesion molecule (EpCAM)-regulated transcription exerted influences on nanomechanical properties of EC cells, which promotes EMT (20). Last, a hospital-based case-control study examined the association between various polymorphisms in base excision repair (BER) DNA pathway genes (OGG1, MUTYH, XRCC1, APEX1, and PARP1) among Japanese postmenopausal women with and without endometrial cancer and found some worthful interaction (21). In MF terms, WNT-activated receptor activity and WNT-protein binding were significantly enriched.

Circular RNAs act as ceRNAs to regulate the expression of their targeted miRNAs. Additionally, miRNAs promote the degradation of target messenger RNAs (mRNAs) or inhibit their translations by recognizing specific binding sites on the 3′-untranslated region (UTR) of mRNAs in either a completely or partially complementary fashion (38). Therefore, these three elements constitute an associated pathway to modulate physiological function. The previous study has reported many miRNAs dysregulated in EC, which may be used as prognostic markers, treatment assessment markers, or treatment targets (39). miRNAs play essential roles in the ontogenetic processes of EC, including cell proliferation, migration, and metastasis (40). For example, mir-505 suppresses EC cell proliferation, invasion, and metastasis by targeting TGFA (41). miR-30c enhances the proliferation of EC cells, and the low expression level of miR-194 contributes to poor prognosis. The expression levels of miR-200c and miR-205 are significantly increased in EC compared with normal tissue (42–44). The silence of miR-124, a novel tumor suppressor miRNA, reverses EMT, and the invasive properties, by attenuating the expression of IQGAP1 (IQ Motif Containing GTPase Activating Protein 1) oncogene (45). Thus, to further understand the impact of the circRNA-related ceRNA crosstalk on MPA-treated EC cells, we used miRNA-circRNA interaction data to construct a circRNA-miRNA network. Hsa_circ_0046843, hsa_circ_0001860, hsa_circ_0020028, hsa_circ_0105045 and hsa_circ_0001993 were the top 5 significant circRNAs in EC cells treated with MPA. Each circRNA paired with five miRNAs, and all these circRNAs could regulate the expression of hsa-miR-4753-3p. Among the miRNAs, miR-296-3p, miR-144-5p, and miR-1236-3p have been reported to play a role in tumor progression. miR-1236-3p is associated with ovarian cancer metastasis (24). miR-296-3p plays a critical role in cell growth and multi-drug resistance in glioblastoma by targeting ether-à-go-go (EAG1) (23). As is known to all, drug resistance and recurrence are the limitations of the clinical application of progesterone treatment. The objective response rate of patients with advanced or recurrent EC is approximately 15 to 20% (46). Thus, miR-296-3p can be further used for progesterone-induced drug resistance. miR-144-5p acts as a tumor suppressor in bladder cancer cells by regulating CCNE1 and CCNE2 (25). miR-296-3p pairs with hsa_circ_0105045, while miR-144-5p and miR-1236-3p pair with hsa_circ_0001860, suggesting the two circRNAs may be associated with cancer progression or drug resistance.

Understanding the mechanism of circRNA-miRNA may provide critical insights into potential strategies for overcoming the shortcomings of progesterone treatment in EC. However, this study also has some limitations. First, this study examined the circRNAs in small EC cell lines treated with progesterone. In order to increase the accuracy of the results, tissues and plasma levels should also be studied respectively in EC patients treated with progesterone. Second, the mechanisms of circRNA-miRNA
interaction are intricate. However, we only constructed a circRNA-miRNA network using five circRNAs. Further study should be concentrated on this interaction. If breakthrough this bottleneck, we can get great achievements in the progesterone treatment of EC.

**Conclusion**

All in all, we acquired 87 differentially expressed circRNAs in EC cell-lines treated with MPA, including 46 up-regulated circRNAs and 41 down-regulated circRNAs. These differentially expressed circRNAs were mainly enriched in many pathways related to cancer, such as response to cholesterol, epithelial to mesenchymal transition, and base-excision repair. Hsa_circ_0046843, hsa_circ_0001860, hsa_circ_0020028, hsa_circ_0105045, and hsa_circ_0001993 were associated with progesterone treated EC, and they can be used as novel biomarkers for EC progression, treatment, or drug resistance. This study improves our knowledge of the molecular mechanisms of progesterone applied in EC, which benefit to further study the roles of circRNAs in EC prognosis, diagnosis, and progesterone therapy.

**Abbreviations**

- circRNA: circular RNA
- EC: endometrial cancer
- MPA: medroxyprogesterone acetate
- RNA-seq: high-throughput RNA sequencing
- qRT-PCR: quantitative real-time reverse transcription
- EMT: Epithelial-to-Mesenchymal Transition
- ceRNA: competing endogenous RNA
- ciRNAs: circular intronic RNA
- ecircRNA: exotic circular RNA
- EiciRNA: exonnic-intron circular RNA
- GO: Gene Ontology
- BP: biological process
Declarations

Ethics approval and consent to participate:
Not applicable.

Consent for publication:
Not applicable.

Availability of data and material:
The data and material of this study were supported by Yudong Wang and Lihua Wang.

Competing interests:
The authors declare that they have no competing interests.

Funding:
This work is supported by the National Natural Science Foundation of China (No. 8157100442).

Authors' contributions:
PZ contributed to design and experimental data collection; WC contributed to data collection; XS and WG contributed to statistical analysis; YW and LW contributed to data analysis and interpretation, and manuscript writing. All authors finally approve the manuscript.

Acknowledgements:
We thank members of our laboratory for helpful discussion.
References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136(5):E359-86.

2. Kalogera E, Dowdy SC, Bakkum-Gamez JN. Preserving fertility in young patients with endometrial cancer: current perspectives. Int J Womens Health. 2014;6:691–701.

3. Zhao S, Li G, Yang L, Li L, Li H. Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate. Oncol Lett. 2013;5(1):139–44.

4. Liu H, Zhang LQ, Zhang XY, Cui ZM. PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy. Oncotargets Ther. 2017;10:2865–71.

5. Yang S, Xiao X, Jia Y, Liu X, Zhang Y, Wang X, et al. Epigenetic modification restores functional PR expression in endometrial cancer cells. Curr Pharm Design. 2014;20(11):1874–80.

6. Gong TT, Li D, Wu QJ, Wang YZ. Cholesterol consumption and risk of endometrial cancer: a systematic review and dose-response meta-analysis of observational studies. Oncotarget. 2016;7(13):16996–7008.

7. Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on Conservative Management of Endometrial Cancer. J Minim Invasive Gynecol. 2018;25(2):308–13.

8. Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–82.

9. Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Keskic V, et al. European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2015;25(7):1258–65.

10. Huang YS, Jie N, Zou KJ, Weng Y. Expression profile of circular RNAs in human gastric cancer tissues. Mol Med Rep. 2017;16(3):2469–76.

11. Wang H, Zhao Y, Chen M, Cui J. Identification of Novel Long Non-coding and Circular RNAs in Human Papillomavirus-Mediated Cervical Cancer. Frontiers in microbiology. 2017;8:1720.

12. Liu L, Li L, Ma X, Yue F, Wang Y, Wang L, et al. Altered Circular RNA Expression in Patients with Repeated Implantation Failure. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2017;44(1):303–13.

13. Xu H, Gong Z, Shen Y, Fang Y, Zhong S. Circular RNA expression in extracellular vesicles isolated from serum of patients with endometrial cancer. Epigenomics. 2018;10(2):187–97.

14. Nishida M, Kasahara K, Kaneko M, Iwasaaki H, Hayashi K. Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Nihon Sanka Fujinka Gakkai Zasshi. 1985;37(7):1103–11.
15. Zhao S, Chen X, Lu X, Yu Y, Feng Y. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma. Gynecol Oncol. 2007;105(1):45–54.

16. Liu J, Wang T, Creighton CJ, Wu SP, Ray M, Janardhan KS, et al. JNK(1/2) represses Lkb(1)-deficiency-induced lung squamous cell carcinoma progression. Nature communications. 2019;10(1):2148.

17. Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: A new star of noncoding RNAs. Cancer letters. 2015;365(2):141–8.

18. Dai M, Zhu XL, Liu F, Xu QY, Ge QL, Jiang SH, et al. Cholesterol Synthetase DHCR24 Induced by Insulin Aggravates Cancer Invasion and Progesterone Resistance in Endometrial Carcinoma. Sci Rep. 2017;7:41404.

19. Abouhashem NS, Ibrahim DA, Mohamed AM. Prognostic implications of epithelial to mesenchymal transition related proteins (E-cadherin, Snail) and hypoxia inducible factor 1alpha in endometrioid endometrial carcinoma. Annals of diagnostic pathology. 2016;22:1–11.

20. Hsu YT, Osmulski P, Wang Y, Huang YW, Liu L, Ruan J, et al. EpCAM-Regulated Transcription Exerts Influences on Nanomechanical Properties of Endometrial Cancer Cells That Promote Epithelial-to-Mesenchymal Transition. Cancer research. 2016;76(21):6171–82.

21. Hosono S, Matsuo K, Ito H, Oze I, Hirose K, Watanabe M, et al. Polymorphisms in base excision repair genes are associated with endometrial cancer risk among postmenopausal Japanese women. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2013;23(9):1561–8.

22. Zhang F, Zhang R, Zhang X, Wu Y, Li X, Zhang S, et al. Comprehensive analysis of circRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of atherosclerosis in rabbits. Aging. 2018;10(9):2266–83.

23. Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L, et al. MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-a-go-go (EAG1). Eur J Cancer. 2013;49(3):710–24.

24. Wang Y, Yan S, Liu X, Zhang W, Li Y, Dong R, et al. miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma. Oncol Rep. 2014;31(4):1905–10.

25. Matsushita R, Seki N, Chiyomaru T, Inoguchi S, Ishihara T, Goto Y, et al. Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer. British journal of cancer. 2015;113(2):282–9.

26. Hsu MT C-pM. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979;26(280):339–40.

27. Shang X, Li G, Liu H, Li T, Liu J, Zhao Q, et al. Comprehensive Circular RNA Profiling Reveals That hsa_circ_0005075, a New Circular RNA Biomarker, Is Involved in Hepatocellular Crcinoma Development. Medicine. 2016;95(22):e3811.
28. Chen S, Li T, Zhao Q, Xiao B, Guo J. Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. Clin Chim Acta. 2017;466:167–71.

29. Li P, Chen S, Chen H, Mo X, Li T, Shao Y, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clinica chimica acta; international journal of clinical chemistry. 2015;444:132–6.

30. Sun Z, Liu J, Zhou Q, Yang S, Yuan W. Comment on "Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer," Cancer Lett. 2017 Mar 1; 388(2017): 208–219. Cancer letters. 2017;404:89–90.

31. Patop IL, Kadener S. circRNAs in Cancer. Curr Opin Genet Dev. 2017;48:121–7.

32. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer research. 2013;73(18):5609–12.

33. Peng L, Yuan XQ, Li GC. The emerging landscape of circular RNA ciRS-7 in cancer (Review). Oncol Rep. 2015;33(6):2669–74.

34. Wang F, Nazarali AJ, Ji S. Circular RNAs as potential biomarkers for cancer diagnosis and therapy. American journal of cancer research. 2016;6(6):1167–76.

35. Wang M, Yu F, Wu W, Zhang Y, Chang W, Ponnumsamy M, et al. Circular RNAs: A novel type of non-coding RNA and their potential implications in antiviral immunity. Int J Biol Sci. 2017;13(12):1497–506.

36. Ng WL, Marinov GK, Liau ES, Lam YL, Lim YY, Ea CK. Inducible RasGEF1B circular RNA is a positive regulator of ICAM-1 in the TLR4/LPS pathway. RNA Biol. 2016;13(9):861–71.

37. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256–64.

38. Wang BG, Li JS, Liu YF, Xu Q. MicroRNA-200b suppresses the invasion and migration of hepatocellular carcinoma by downregulating RhoA and circRNA_000839. Tumour biology: the journal of the International Society for Oncodevelopmental Biology Medicine. 2017;39(7):1010428317719577.

39. Srivastava SK, Ahmad A, Zubair H, Miree O, Singh S, Rocconi RP, et al. MicroRNAs in gynecological cancers: Small molecules with big implications. Cancer letters. 2017;407:123–38.

40. Kanekura K, Nishi H, Isaka K, Kuroda M. MicroRNA and gynecologic cancers. J Obstet Gynaecol Res. 2016;42(6):612–7.

41. Chen S, Sun KX, Liu BL, Zong ZH, Zhao Y. MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-alpha. Mol Cancer. 2016;15:11.

42. Karaayvaz M, Zhang C, Liang S, Shroyer KR, Ju J. Prognostic significance of miR-205 in endometrial cancer. PloS one. 2012;7(4):e35158.

43. Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J. Prognostic significance of miR-194 in endometrial cancer. Biomarker research. 2013;1.
44. Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y, et al. Estrogen regulates the tumour suppressor MiRNA-30c and its target gene, MTA-1, in endometrial cancer. PloS one. 2014;9(3):e90810.

45. Dong P, Ihira K, Xiong Y, Watari H, Hanley SJ, Yamada T, et al. Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression. Oncotarget. 2016;7(15):20260–70.

46. Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010;28(1):81–90.

Figures
Figure 1

Bioinformatic analysis of circRNA expression pattern in ISK cell lines treated with MPA compared with untreated. A: Scatter plot was conducted to exhibit the circRNA expression distribution. The scatter plot is a visualization method used for assessing the variation in circRNA expression between ISK cell lines treated with MPA and untreated cells. The values corresponding to the X- and Y-axes in the scatter plot are the normalized signal values of the samples (log2 scaled). The lines represent the default significant
fold change (2.0). B: Volcano plot was created to show significantly dysregulated circRNAs. The vertical green lines corresponded to two-fold up- and down-regulation (log2 scaled), and the horizontal green line represented a p value of 0.05. The red points represented significantly dysregulated circRNAs (fold change ≥2.0, p < 0.05). C: Heat map evaluation of the circRNA expression patterns among cells treated with MPA and untreated cells. Each column represents the expression profile of a cell line sample, and each row corresponds to a circRNA. “Red” indicates higher expression level, and “green” indicates lower expression level.

Figure 2

CircRNAs functional enrichment analysis. A: Gene ontology (GO) terms for the parental genes of upregulated circRNAs. B: Gene ontology (GO) terms for the parental genes of down-regulated circRNAs. C: KEGG pathways for the parental genes of up-regulated circRNAs. D: KEGG pathways for the parental genes of down-regulated circRNAs.
Figure 3

CircRNA-miRNA interaction network
Figure 4

Validation of the differentially expressed circRNAs by real-time PCR assay. The values are mean ± SE (n = 3). *: P < 0.05
Figure 5

5A. The analysis of effects of MPA treatment and of knockdown of circ-001806 in ISK cells. A. qRT-PCR analysis of relative circRNA expression. B. Cell proliferation analysis using MTS assay. *, P < 0.05. C. Invasion assay using invasion chamber and 4% PFA fixed cells were labelled using 0.1% Crystal violet dye (Blue color). D. qRT-PCR analysis of miRNA expression in ISK cells.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalData5CircRNAseq.docx
- SupplementalData1PCAtotal.png
- SupplementalData2clusterofhostinggenes.png
- SupplementalData3hostinggenes.xlsx
• SupplementalData4networkparameter.xlsx